LEO Pharma Deal History & Licensing Activity
LEO Pharma is a specialty pharma headquartered in Denmark. Over the past three years, LEO Pharma has been involved in 3 licensing and acquisition transactions, with a primary focus on Gene Therapy (4 deals). The company currently has 15 active clinical trials, primarily in Autoimmune.
Deals (12mo)
2
Active Trials
15
Top Modality
Gene Therapy
Focus Area
Autoimmune
LEO Pharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving LEO Pharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| skin disease gene therapy | Replay | Gene Therapy | Unknown | license | Apr 2026 |
| skin disease gene therapy | Replay | Gene Therapy | Unknown | acquisition | Apr 2026 |
LEO Pharma Pipeline Focus
Therapeutic areas and modalities where LEO Pharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
LEO Pharma Strategic Signals
Key indicators of LEO Pharma's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
LEO Pharma Clinical Pipeline
LEO Pharma has 15 active clinical trials across 5 development phases.
6
Unknown
2
Not Applicable
2
Phase 4
3
Phase 2
2
Phase 3
See How Your Asset Matches LEO Pharma's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Mab Benchmarks
Upfront, milestone, and royalty benchmarks for mab deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About LEO Pharma Licensing & Deal Activity
LEO Pharma is a specialty pharma company based in Denmark that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, LEO Pharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for LEO Pharma include Autoimmune (11 deals and trials), Mega Deals (4 deals and trials), Dermatology (1 deal and trial), and Cardiovascular (1 deal and trial). In terms of modality, LEO Pharma has shown particular interest in gene therapy, mab.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for LEO Pharma and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against LEO Pharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.